Search Within

David Hyman

  1. "Division of Subspecialty Medicine "
Formats
  1. Journal Article (18)
  2. Meeting Abstract (13)
Groups
  1. Department of Medicine (31)
  2. Division of Subspecialty Medicine (31)
  3. Early Drug Development Service (31)
  4. Solid Tumor Oncology Division (31)
  5. Survivorship Research (25)
  6. GSK Faculty (21)

More Groups

People
  1. Mario Lacouture (18)
  2. David Solit (12)
  3. Eli Diamond (12)
  4. Omar Abdel-Wahab (12)
  5. Michael Berger (11)
  6. Alexander Drilon (9)

More People

Years
  1. 2022 (1)
  2. 2021 (1)
  3. 2020 (5)
  4. 2019 (4)
  5. 2018 (7)
  6. 2017 (3)

More Years

Publications
  1. Cancer Discovery (4)
  2. Journal of Clinical Oncology (4)
  3. Blood (3)
  4. Annals of Oncology (2)
  5. Cancer (2)
  6. Cancer Research (2)

More Publications

Publishers
  1. American Association for Cancer Research (7)
  2. American Society of Clinical Oncology (4)
  3. American Society of Hematology (4)
  4. Nature Publishing Group (4)
  5. Springer (3)
  6. Oxford University Press (2)

More Publishers

Results (31)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy of MEK inhibition in patients with histiocytic neoplasms
    Journal Article

    Diamond, E. L.; Durham, B. H.; Ulaner, G. A.; Drill, E.; Buthorn, J.; Ki, M.; Bitner, L.; Cho, H.; Young, R. J.; Francis, J. H.; more...
    Nature (2019)

    Fulltext@MSK | Save
  • Genomic landscape, clinical characteristics and outcomes of early onset (EO) compared with average onset (AO) colorectal cancer (CRC)
    Meeting Abstract

    Dos Santos Fernandes, G.; Chatila, W. K.; Yaeger, R.; Mendelsohn, R. B.; Stadler, Z. K.; Segal, N. H.; Varghese, A. M.; Lagunes, D. R.; Diaz, L. A.; Shia, J.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Utilization, safety, and efficacy of the FDA compassionate use program
    Meeting Abstract

    Feit, N.; Smith, E.; Cambria, R.; Anopa, J.; Deighan, J.; Pamer, E.; Wilson, R.; Greenfield, J.; Zivanovic, O.; Hyman, D.
    European Journal of Cancer (2018)

    Fulltext@MSK | Save
  • Comparing metastatic (M) young onset (YO) colorectal cancer (CRC) with average onset (AO): Do they differ clinically and genetically?
    Meeting Abstract

    Dos Santos Fernandes, G.; Chatila, W.; Yaeger, R.; Mendelsohn, R.; Stadler, Z.; Segal, N. H.; Varghese, A.; Reidy, D.; Diaz, L.; Shia, J.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell histiocytosis analysis of data from the histology-independent, phase 2, open-label VE-BASKET study
    Journal Article

    Diamond, E. L.; Subbiah, V.; Lockhart, A. C.; Blay, J. Y.; Puzanov, I.; Chau, I.; Raje, N. S.; Wolf, J.; Erinjeri, J. P.; Torrisi, J.; more...
    JAMA Oncology (2018)

    Fulltext@MSK | Save
  • Single-agent dabrafenib for BRAF(V600E)-mutated histiocytosis
    Journal Article

    Bhatia, A.; Ulaner, G.; Rampal, R.; Hyman, D. M.; Abdel-Wahab, O.; Durham, B. H.; Dogan, A.; Ozkaya, N.; Lacouture, M. E.; Hajdenberg, J.; more...
    Haematologica (2018)

    Fulltext@MSK | Save
  • Genetic predictors of response to systemic therapy in esophagogastric cancer
    Journal Article

    Janjigian, Y. Y.; Sanchez-Vega, F.; Jonsson, P.; Chatila, W. K.; Hechtman, J. F.; Ku, G. Y.; Riches, J. C.; Tuvy, Y.; Kundra, R.; Bouvier, N.; more...
    Cancer Discovery (2018)

    Fulltext@MSK | Save
  • First-in-class ERK1/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: Results of a phase I dose-escalation and expansion study
    Journal Article

    Sullivan, R. J.; Infante, J. R.; Janku, F.; Lee Wong, D. J.; Sosman, J. A.; Keedy, V.; Patel, M. R.; Shapiro, G. I.; Mier, J. W.; Tolcher, A. W.; more...
    Cancer Discovery (2018)

    Fulltext@MSK | Save
  • First-in-class oral ERK1/2 inhibitor Ulixertinib (BVD-523) in patients with advanced solid tumors: Final results of a phase I dose escalation and expansion study
    Meeting Abstract

    Li, B. T.; Janku, F.; Patel, M. R.; Sullivan, R. J.; Flaherty, K.; Buchbinder, E. I.; Lacouture, M. E.; Varghese, A. M.; Wong, D. J. L.; Sznol, M.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel
    Journal Article

    Smyth, L. M.; Monson, K. R.; Jhaveri, K.; Drilon, A.; Li, B. T.; Abida, W.; Iyer, G.; Gerecitano, J. F.; Gounder, M.; Harding, J. J.; more...
    Investigational New Drugs (2017)

    Fulltext@MSK | Save